ArticleJournal of the Endocrine Society2026
Relationship between histopathological findings and RAI in non-papillary follicular cell-derived thyroid carcinoma.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between histopathological findings and RAI in non-papillary follicular cell-derived thyroid carcinoma.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Detailed studies considering the distinct types of non-papillary follicular cell-derived thyroid carcinoma in terms of radioactive iodine (RAI) avidity are limited. Objective: This study aimed to investigate clinicopathological characteristics, relationship between histopathological findings, including solid/trabecular/insular (STI) components and RAI treatment (RAIT), in patients with non-papillary follicular cell-derived thyroid carcinoma. Methods: This study included 114 patients with non-papillary follicular cell-derived thyroid carcinoma who underwent first RAIT between January 2005 and August 2025. Results: Of the 114 patients, 5 (4%) were minimally invasive follicular thyroid carcinoma (MI-FTC), 41 (36%) were encapsulated angio-invasive FTC (EA-FTC), 23 (20%) were widely invasive FTC (WI-FTC), 22 (19%) were differentiated high-grade thyroid carcinoma (DHGTC), 21 (18%) were poorly differentiated thyroid carcinoma (PDTC), and 2 (2%) were others, respectively. The median percentages of STI component was 40% (range, 0%-10%) in all patients, 5% (range, 0%-50%) in MI-FTC, 30% (range, 0%-100%) in EA-FTC, 30% (range, 0%-100%) in WI-FTC, 28% (range, 5%-70%) in DHGTC, and 70% (range, 50%-100%) in PDTC, respectively. Among the 114 patients, the rate of RAI avidity was 60% (95% CI, 49%-71%) (47/78) in lung, 89% (95% CI, 79%-96%) (59/66) was in bone, 100% (13/13) in lymph node, and 100% (3/3) in other sites, respectively. Conclusion: RAI avidity was relatively high in non-papillary follicular cell-derived thyroid carcinoma, regardless of the histological type and percentage of STI components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.